← Back to Clinical Trials
Recruiting NCT07451873

NCT07451873 Glycocalyx and Oxidative Stress in Endothelial Function (Part 2)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07451873
Status Recruiting
Phase
Sponsor Josip Juraj Strossmayer University of Osijek
Condition Coronary Heart Disease
Study Type OBSERVATIONAL
Enrollment 35 participants
Start Date 2025-10-01
Primary Completion 2029-09-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 35 participants in total. It began in 2025-10-01 with a primary completion date of 2029-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The primary research objective of the project is to determine the role of eGC in microvascular reactivity in patients with coronary heart disease (CHD) before and after bypass grafting (cross-sectional study 2).The main objective of the project is to increase the excellence and interdisciplinarity of scientific work at MEFOS by connecting researchers from different scientific fields, improving conditions and resources for scientific work, and increasing international cooperation, in line with strategic objective 1: raising scientific excellence. The results of the project could provide pathophysiological insight into the development and maintenance of endothelial dysfunction in CVD, as well as identify new biomarkers for CVD.

Eligibility Criteria

Inclusion Criteria: * adult patients of both sexes over 18 years of age * Caucasian * undergoing elective coronary artery bypass grafting (CABG) * provided written informed consent Exclusion Criteria: * emergency surgery * sepsis or severe systemic inflammation before surgery * severe renal or hepatic insufficiency * immunosuppression * serious comorbidities (e.g., active cancer) * therapies that could affect oxidative stress (e.g., high doses of corticosteroids)

Contact & Investigator

Central Contact

Ines Drenjančević, MD, PhD

✉ ines.drenjancevic@mefos.hr

📞 +385912241406

Frequently Asked Questions

Who can join the NCT07451873 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07451873 currently recruiting?

Yes, NCT07451873 is actively recruiting participants. Contact the research team at ines.drenjancevic@mefos.hr for enrollment information.

Where is the NCT07451873 trial being conducted?

This trial is being conducted at Osijek, Croatia.

Who is sponsoring the NCT07451873 clinical trial?

NCT07451873 is sponsored by Josip Juraj Strossmayer University of Osijek. The trial plans to enroll 35 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology